Citigroup Inc. Buys 8,804 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Citigroup Inc. boosted its stake in shares of Bausch Health Companies Inc. (NYSE:BHC) by 73.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,820 shares of the company’s stock after acquiring an additional 8,804 shares during the quarter. Citigroup Inc.’s holdings in Bausch Health Companies were worth $172,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Lazard Asset Management LLC bought a new stake in Bausch Health Companies during the 2nd quarter worth about $49,000. Graham Capital Management L.P. acquired a new position in Bausch Health Companies during the 2nd quarter valued at about $84,000. FMR LLC lifted its position in Bausch Health Companies by 58.3% during the 2nd quarter. FMR LLC now owns 10,057 shares of the company’s stock valued at $84,000 after purchasing an additional 3,703 shares during the period. Ausdal Financial Partners Inc. acquired a new position in Bausch Health Companies during the 3rd quarter valued at about $86,000. Finally, Jump Financial LLC acquired a new position in Bausch Health Companies during the 3rd quarter valued at about $92,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

Shares of NYSE:BHC opened at $10.61 on Friday. The company has a market capitalization of $3.88 billion, a price-to-earnings ratio of -6.55 and a beta of 0.83. The firm’s 50 day simple moving average is $8.92 and its 200 day simple moving average is $8.05. The company has a debt-to-equity ratio of 74.20, a current ratio of 1.30 and a quick ratio of 0.94. Bausch Health Companies Inc. has a fifty-two week low of $5.57 and a fifty-two week high of $10.80.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Thursday, February 22nd. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.01 by $0.14. The firm had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The business’s quarterly revenue was up 9.8% on a year-over-year basis. During the same period last year, the company posted $1.02 EPS. As a group, sell-side analysts forecast that Bausch Health Companies Inc. will post 3.95 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on BHC shares. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th. Royal Bank of Canada upped their target price on shares of Bausch Health Companies from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Friday, February 23rd. Finally, Jefferies Financial Group cut their target price on shares of Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, February 20th.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.